# Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

Study · id `cardio:ct-nct06478186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06478186](<https://clinicaltrials.gov/study/NCT06478186>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06478186

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06478186. Randomized; triple masking; primary purpose treatment. Start 2024-08-16 (actual); primary completion 2026-12-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06478186, source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)
- Started: 2024-08-16 (actual) (ClinicalTrials.gov record NCT06478186, source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-16 (anticipated) (ClinicalTrials.gov record NCT06478186, source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)
- Completion: 2027-01-16 (anticipated) (ClinicalTrials.gov record NCT06478186, source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06478186, source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06478186-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
- Condition: Osteoarthritis, Knee
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): triamcinolone acetonide extended-release injectable suspension; TCA-ER
- Intervention (Drug): Triamcinolone Acetonide- Immediate Release;TCA-IR
- Lead sponsor: University of Kansas Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Kansas Medical Center (`cardio:org-university-of-kansas-medical-center`)

## Provenance

Content hash: ca2db85a050e5717c3cad40172d7ba9fe0f9703d51dcf4687fde24852f355073
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
